Search Results - "DEENIK, Wendy"

MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis by Vermaat, Joost S, Somers, Sebastiaan F, de Wreede, Liesbeth C, Kraan, Willem, de Groen, Ruben A L, Schrader, Anne M R, Kerver, Emile D, Scheepstra, Cornelis G, Berenschot, Henriëtte, Deenik, Wendy, Wegman, Jurgen, Broers, Rianne, de Boer, Jan-Paul D, Nijland, Marcel, van Wezel, Tom, Veelken, Hendrik, Spaargaren, Marcel, Cleven, Arjen H, Kersten, Marie José, Pals, Steven T

“…The 2016 World Health Organization classification defines diffuse large B-cell lymphoma (DLBCL) subtypes based on Epstein-Barr virus (EBV) infection and…”
Get full text

Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study by Nielsen, Lene Kongsgaard, Stege, Claudia, Lissenberg-Witte, Birgit, van der Holt, Bronno, Mellqvist, Ulf-Henrik, Salomo, Morten, Bos, Gerard, Levin, Mark-David, Visser-Wisselaar, Heleen, Hansson, Markus, van der Velden, Annette, Deenik, Wendy, Coenen, Juleon, Hinge, Maja, Klein, Saskia, Tanis, Bea, Szatkowski, Damian, Brouwer, Rolf, Westerman, Matthijs, Leys, Rineke, Sinnige, Harm, Haukås, Einar, van der Hem, Klaas, Durian, Marc, Gimsing, Peter, van de Donk, Niels, Sonneveld, Pieter, Waage, Anders, Abildgaard, Niels, Zweegman, Sonja

“…Data on the impact of long term treatment with immunomodulatory drugs (IMiD) on health-related quality of life (HRQoL) is limited. The HOVON-87/NMSG18 study…”
Get full text

P1159: INFERIOR OUTCOME OF FRAIL AND UNFIT PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA TREATED WITH ATTENUATED R‐CHOP by Al‐Sarayfi, Diana, Brink, Mirian, Chamuleau, Martine E. D., Brouwer, Rolf, Rijn, Roos, Issa, Djamila, Deenik, Wendy, Huls, Gerwin, Mous, Rogier, Vermaat, Joost S.P., Zijlstra, Josee M., Meerten, Tom, Nijland, Marcel

Get full text

Thrombocytopenia in a nutshell by Achterbergh, Roos, Dr, Vermeer, Henricus J, PhD, Curtis, Brian R, PhD, Porcelijn, Leendert, MD, Aster, Richard H, MD, Deenik, Wendy, MD, Daemen-Gubbels, Catharine, MD

“…Examples reported were associated with consumption of an African bean,2 sesame seeds,3 cranberry juice,4 cow's milk, and Jui (a Chinese herbal medicine).5 To…”
Get full text

Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia by DEENIK, Wendy, JANSSEN, Jeroen J. W. M, SONNEVELD, Pieter, VAN MARWIJK KOOY, Marinus, WITTEBOL, Shulamit, WILLEMZE, Roelof, WIJERMANS, Pierre W, BEVERLOO, H. Berna, LÖWENBERG, Bob, VALK, Peter J. M, OSSENKOPPELE, Gert J, CORNELISSEN, Jan J, VAN DER HOLT, Bronno, VERHOEF, Gregor E. G, SMIT, Willem M, KERSTEN, Marie José, DAENEN, Simon M. G. J, VERDONCK, Leo F, FERRANT, Augustin, SCHATTENBERG, Anton V. M. B

“…In order to improve the molecular response rate and prevent resistance to treatment, combination therapy with different dosages of imatinib and cytarabine was…”
Get full text

Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON) by Thielen, Noortje, van der Holt, Bronno, Cornelissen, Jan J, Verhoef, Gregor E.G, Gussinklo, Titia, Biemond, Bart J, Daenen, Simon M.G, Deenik, Wendy, van Marwijk Kooy, Rien, Petersen, Eefke, Smit, Willem M, Valk, Peter J.M, Ossenkoppele, Gert J, Janssen, Jeroen J.W.M

“…Abstract Background Tyrosine kinase inhibitors treatment in responding chronic myeloid leukaemia (CML) patients is generally continued indefinitely. In this…”
Get full text

Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study by Stege, Claudia A.M., Nasserinejad, Kazem, Levin, Mark-David, Klein, Saskia K., Waal, Esther de, Eeltink, Corien, Korst, Charlotte L.B.M., Ypma, Paula F, Dijk, Amanda C., Westerman, Matthijs, Deenik, Wendy, Tanis, Bea, Minnema, Monique C, Verheul, Henk M.W., Lissenberg-Witte, Birgit I., van de Donk, Niels WCJ, Sonneveld, Pieter, Zweegman, Sonja

“…Introduction There is a high rate of treatment discontinuation (TD) in elderly patients with nte-NDMM, that negatively impacts overall survival (OS). In order…”
Get full text

Feasibility and Efficacy of Dose Adjusted Melphalan - Prednisone - Bortezomib (MPV) in Elderly Patients ≥ 75 Years of Age with Newly Diagnosed Multiple Myeloma; the Non-Randomised Phase II HOVON 123 Study by Zweegman, Sonja, Levin, Mark-David, Klein, Saskia K., De Waal, Esther G.M., Eeltink, Corien M., Ypma, Paula F., Dijk, Amanda C., Westerman, Matthijs, Deenik, Wendy, Tanis, Bea, Slee-Valentijn, Monique S., Minnema, Monique, Visser-Wisselaar, Heleen, Stege, Claudia, van de Donk, Niels W.C.J., Nasserinejad, Kazem, Sonneveld, Pieter

“…BACKGROUND There is a high rate of toxicity-related discontinuation in elderly patients with NDMM, which in general is higher in patients ≥75 years. Therefore,…”
Get full text

Lenalidomide with or without Erythropoietin and Granulocyte-Colony Stimulating Factor Shows Efficacy in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndrome with or without Del 5q, Refractory or Unlikely to Respond to Erythropoietin. Results of a HOVON89 Phase II Randomized Multicenter Study. (EudraCT 2008-002195-10) by van de Loosdrecht, Arjan A., Chitu, Dana A, Cremers, Eline MP, Westers, Theresia M, Alhan, Canan, Visser-Wisselaar, Heleen, Verbrugge, Annelies, Muus, Petra, de Greef, Inge, Wijermans, Pierre W, Jansen, Joop H., Klein, Saskia K., Vellenga, Edo, Legdeur, Marie-Cecile, Deenik, Wendy, jongen-Lavrencic, Mojca, van Marwijk-Kooy, Rien, Tanis, Bea, Wegman, Jurgen, van Maanen, Tanja, Ossenkoppele, Gert

“…▪ Purpose: This randomized phase II study (HOVON89) in patients with low/int-1 risk MDS refractory or unlikely to respond to erythropoietin and…”
Get full text

Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group by Stege, Claudia A.M., van der Holt, Bronno, Mellqvist, Ulf-Henrik, Levin, Mark-David, Salomo, Morten, Abildgaard, Niels, Bos, Gerard, Visser-Wisselaar, Heleen, Hansson, Markus, van der Velden, Annette, Deenik, Wendy, Gruber, Astrid, Coenen, Jules L.L.M., Plesner, Torben, Klein, Saskia, Tanis, Bea, Szatkowski, Damian L., Brouwer, Rolf, Westerman, Matthijs, Leijs, Maria Berhardina, Sinnige, Harm, Haukaas, Einar, van der Hem, Klaas, Durian, Marc, Mattijssen, Vera, Gimsing, Peter, Van De Donk, Niels WCJ, Stevens-Kroef, Marian, Sonneveld, Pieter, Waage, Anders, Zweegman, Sonja

“…Introduction We previously reported the results of the phase III randomized HOVON-87/NMSG-18 study for Newly Diagnosed Multiple Myeloma patients not eligible…”
Get full text

Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib by Deenik, Wendy, van der Holt, Bronno, Janssen, Jeroen J.W.M., Chu, Isabel W.T., Valk, Peter J.M., Ossenkoppele, Gert J., van der Heiden, Ilse P., Sonneveld, Pieter, van Schaik, Ron H.N., Cornelissen, Jan J.

Get full text

A case of methemoglobinemia after ingestion of a chlorhexidine in alcohol solution in an alcohol-dependent patient by Kuypers, Maybritt I., Lieshoud, Jeroen R. van, van der Linden, Paul D., Touw, Daan J., Deenik, Wendy, Boeke, Gesiena M.

Get full text

Randomized Phase III Trial in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma Comparing Melphalan-Prednisone-Thalidomide Followed By Thalidomide Maintenance (MPT-T) Versus Melphalan-Prednisone-Lenalidomide Followed By Maintenance with Lenalidomide (MPR-R); A Joint Study of the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and the Nordic Myeloma Study Group (NMSG) by Zweegman, Sonja, Holt, Bronno van der, Mellqvist, Ulf-Henrik, Salomo, Morten, Bos, Gerard M.J., Levin, Mark-David, Visser-Wisselaar, Heleen A, Hansson, Markus, van der Velden, Annette WG, Deenik, Wendy, Gruber, Astrid, Coenen, Juleon LLM, Plesner, Torben, Klein, Saskia K, Tanis, Bea, Szatkowski, Damian L, Brouwer, Rolf, Westerman, Matthijs, Leys, M (Rineke) BL, van de Donk, Niels W.C.J., Haukås, Einar, van der Hem, Klaas, Durian, MF, Mattijssen, E (Vera) JM, Sinnige, Harm AM, Stevens-Kroef, Marian JPL, Sonneveld, Pieter, Waage, Anders

“…▪ Background Melphalan-based regimens, combined with Prednisone and Thalidomide (THAL)(MPT) or Bortezomib (V)(MPV), have been approved as standard therapy of…”
Get full text

A New Flowcytometry-Based Method to Discriminate Malignant From Normal Stem Cells in CML by Janssen, Jeroen J.W.M., Deenik, Wendy, Smolders, Karlijn G.M., Terwijn, Monique, Kelder, Angele, Cornelissen, J.J., Schuurhuis, Gerrit-Jan, Ossenkoppele, Gert J.

“…Abstract 3245 Poster Board III-182 Tyrosine kinase inhibitor (TKI) insensitivity of CML hematopoietic stem cells prevents eradication of the disease by these…”
Get full text

Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1) Predict for Molecular Resistance in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) Receiving High-Dose Imatinib by Deenik, Wendy, van der Holt, Bronno, Janssen, Jeroen JWM, Chu, Isabel W.T., Valk, Peter, Ossenkoppele, Gert, van der Heiden, Ilse, Sonneveld, Pieter, van Schaik, Ron, Cornelissen, Jan J.

“…Abstract 2208 Poster Board II-185 Hematologic and cytogenetic responses to first-line imatinib are high in patients with chronic myeloid leukemia (CML), but…”
Get full text

Clear cell sarcoma (malignant melanoma) of soft parts : A clinicopathologic study of 30 cases by DEENIK, W, MOOI, W. J, RUTGERS, E. J, PETERSE, J. L, HART, A. A, KROON, B. B

“…Clear cell sarcoma, or malignant melanoma of soft parts, is a rare tumor that occurs predominantly in the extremities of young adults. The importance of…”
Get full text

High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group by Thielen, Noortje, van der Holt, Bronno, Verhoef, Gregor E. G., Ammerlaan, Rianne A. H. M., Sonneveld, Pieter, Janssen, Jeroen J. W. M., Deenik, Wendy, Falkenburg, J. H. Frederik, Kersten, Marie José, Sinnige, Harm A. M., Schipperus, Martin, Schattenberg, Anton, van Marwijk Kooy, Rien, Smit, Willem M., Chu, Isabel W. T., Valk, Peter J. M., Ossenkoppele, Gert J., Cornelissen, Jan J.

“…Despite the revolutionary change in the prognosis of chronic myeloid leukemia (CML) patients with the introduction of imatinib, patients with resistant disease…”
Get full text

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia by Deenik, Wendy, van der Holt, Bronno, Verhoef, Gregor E.G., Smit, Willem M., Kersten, Marie J., Kluin-Nelemans, Hanneke C., Verdonck, Leo F., Ferrant, Augustin, Schattenberg, Anton V. M.B., Janssen, Jeroen J. W.M., Sonneveld, Pieter, van Marwijk Kooy, Marinus, Wittebol, Shulamit, Willemze, Roelof, Wijermans, Pierre W., Westveer, Petra H.M., Beverloo, H. Berna, Valk, Peter, Löwenberg, Bob, Ossenkoppele, Gert J., Cornelissen, Jan J.

“…The HOVON cooperative study group performed a feasibility study of escalated imatinib and intravenous cytarabine in 165 patients with early chronic-phase…”
Get full text

Clear cell sarcoma (malignant melanoma) of soft parts by Deenik, Wendy, Mooi, Wolter J., Rutgers, Emiel J., Peterse, Johannes L., Hart, Augustinus A., Kroon, Bin B.

“…BACKGROUND Clear cell sarcoma, or malignant melanoma of soft parts, is a rare tumor that occurs predominantly in the extremities of young adults. The…”
Get full text